

1 **Genome-wide analysis of genetic pleiotropy and causal genes across**
2 **three age-related ocular disorders**

3
4 Xueming Yao,¹ Hongxi Yang,^{2,a} Han Han,¹ Xuejing Kou,¹ Yuhan Jiang,³ Menghan Luo,³ Yao

5 Zhou,³ Jianhua Wang,³ Xutong Fan,³ Xiaohong Wang,^{2,*} Mulin Jun Li,^{2,3,*} Hua Yan,^{1,4,5,*}

6

7 ¹ Department of Ophthalmology, Tianjin Medical University General Hospital, Tianjin, 300052,
8 China.

9 ² Department of Pharmacology, Tianjin Key Laboratory of Inflammation Biology, School of Basic
10 Medical Sciences, Tianjin Medical University, Tianjin, 300070, China.

11 ³ Department of Bioinformatics, The Province and Ministry Co-sponsored Collaborative
12 Innovation Center for Medical Epigenetics, School of Basic Medical Sciences, Tianjin Medical
13 University, Tianjin, 300070, China.

14 ⁴ Laboratory of Molecular Ophthalmology, Tianjin Medical University, Tianjin, 300070, China.

15 ⁵ School of Medicine, Nankai University, Tianjin, 300071, China.

16 *Correspondence: xiaohongwang@tmu.edu.cn (X.W.), mulin@tmu.edu.cn (M.J.L.),

17 zyyyanhua@tmu.edu.cn (H.Y.)

^a X.Y. and H.Y. contributed equally.

18 **Abstract**

19 Age-related macular disorder (AMD), cataract, and glaucoma are leading causes of blindness
20 worldwide. Previous genome-wide association studies (GWASs) have revealed a variety of
21 susceptible loci associated with age-related ocular disorders, yet the genetic pleiotropy and causal
22 genes across these diseases remain poorly understood. By leveraging large-scale genetic and
23 observational data from ocular disease GWASs and UK Biobank (UKBB), we found significant
24 pairwise genetic correlations and consistent epidemiological associations among these ocular
25 disorders. Cross-disease meta-analysis uncovered ten pleiotropic loci, four of which were
26 replicated in an additional cohort. Integration of variants in pleiotropic loci and multiple
27 single-cell omics data identified that Müller cells and astrocytes were likely causal cell types
28 underlying ocular comorbidity. In addition, we comprehensively integrated eye-specific gene
29 expression quantitative loci (eQTLs), epigenomic profiling, and 3D genome data to prioritize
30 causal pleiotropic genes. We found that pleiotropic genes were essential in nerve development and
31 eye pigmentation, and targetable by existing drugs for the treatment of single ocular disorder.
32 These findings will not only facilitate the mechanistic research of ocular comorbidities but also
33 benefit the therapeutic optimization of age-related ocular diseases.

34

35 **Introduction**

36 Age-related ocular diseases, such as age-related macular degeneration (AMD), cataract, and
37 glaucoma, are among the leading causes of irreversible blindness and vision impairment in adults
38 aged ≥ 50 years worldwide ¹. Previous cross-sectional and case-control studies have reported that
39 cataract and glaucoma commonly co-exist and prevalent glaucoma is associated with neovascular
40 AMD ^{2;3}. A clinical study also showed that over 20% of eye samples from the patients listed for
41 cataract surgery have evidence of AMD according to optical coherence tomography imaging ⁴.
42 The findings motivate the exploration of the extent and causal factors for potential comorbidity
43 among these age-related ocular diseases.

44

45 Recent genome-wide association studies (GWASs) have identified hundreds of genetic signals that
46 contribute to the complex pathogenesis of AMD ^{5;6}, cataract ⁷ and glaucoma ⁸⁻¹⁰. These and other
47 genetic studies also suggest a high heritability in susceptibility of AMD (~50%) ¹¹, cataract
48 (35-58%) ^{12;13}, and glaucoma (35-65%) ^{14;15}. Nevertheless, the shared genetic architecture among
49 these age-related ocular diseases is largely unknown. A study investigated the genetic pleiotropy
50 among AMD and several eye-related diseases/traits, and found that patients with AMD
51 demonstrate a genetically reduced risk to develop open-angle glaucoma ¹⁶, which is inconsistent
52 with other findings ^{17;18}. Moreover, no genetic pleiotropy research has been conducted between
53 cataract and other ocular diseases so far. Given the conflicting results and scant knowledge
54 regarding the shared genetic architecture of these age-related ocular disorders, more systematic
55 investigation based on larger and complementary cohorts is needed.

56

57 While different levels of genetic correlations or pleiotropic loci can be faithfully estimated among
58 ocular diseases/traits, the pleiotropic genes and causal variants have not been rigorously examined.
59 This is an important issue to clarify, as the shared biological basis of ocular disorders could
60 represent potential efficient intervention targets for the prevention and treatment of ocular
61 comorbidities. Emerging tissue/cell type-specific epigenomic profiles, single-cell omics atlas as
62 well as molecular phenotype quantitative trait loci (QTLs) mapping on certain ocular diseases
63 revealed many causal variants and genes underlying cell type specificity of disease etiology¹⁹⁻²³.
64 Thus, integrating large-scale multi-omics and QTL data from eyes with disease pleiotropy
65 information would provide a promising strategy to decipher the genetic causality of ocular
66 comorbidities, especially for the majority of causal variants in the non-coding genomic regions.

67

68 Here, by leveraging large-scale genetic and observational data from public GWASs and UK
69 Biobank (UKBB), we systematically investigated the genetic sharing patterns and epidemiological
70 associations of three age-related ocular diseases including AMD, cataract, and glaucoma. We
71 found extensive genetic pleiotropy and pairwise connections among these three diseases and
72 identified ten pleiotropic loci across the genome. To better understand the mechanism underlying
73 these pleiotropic loci, the integration of eye-specific gene expression (eQTLs), epigenomic
74 profiling, and 3D genome data were conducted to probe causal pleiotropic genes. Finally, drug
75 repurposing was conducted by utilizing molecular networks for potential treatment or prevention
76 of ocular comorbidities.

77

78 **Material and methods**

79 **GWAS summary statistics collection**

80 Full GWAS summary statistics of European ancestry on AMD, cataract, and glaucoma with the
81 largest sample size were obtained after searching eight databases (GWAS Catalog ²⁴, UKBB ²⁵,
82 GeneAtlas ²⁶, GWAS Atlas ²⁷, LD Hub ²⁸, GRASP ²⁹, PhenoScanner ³⁰, and dbGaP ³¹). GWAS
83 summary statistics with available signed statistics (beta or odds ratio), effect alleles, and
84 non-effect alleles were retained during the search. We also collected GWAS summary data from
85 FinnGen for replication analysis ³². More detailed information regarding the selected GWAS
86 summary statistics for AMD, cataract, and glaucoma was shown in **Table S1**.

87

88 **Estimation of genetic correlation**

89 Using GWAS summary statistics derived from the above datasets with a sample size > 50,000 and
90 the number of cases and controls > 10,000, we conducted LD Score regression (LDSC) ³³ for
91 these ocular diseases to estimate pairwise genetic correlations. SNPs were filtered to HapMap3
92 SNPs to avoid bias due to inconsistent imputation quality. SNPs with INFO ≤ 0.9 , minor allele
93 frequency ≤ 0.01 , non-SNP variants, strand-ambiguous SNPs, and SNPs with duplicate IDs were
94 removed. Pre-computed linkage disequilibrium (LD) scores and regression weights for European
95 populations of the 1000 Genomes project were downloaded from the LDSC website
96 (http://www.broadinstitute.org/~bulik/eur_ldscores/). We ensured that the LD score regression
97 intercepts for AMD, cataract, and glaucoma were close to 1 during estimations. Moreover, genetic
98 correlations between these diseases were also estimated using another tool SumHer from LDAK ³⁴
99 under the recommended LDAK-Thin model. A tagging file computed using 2,000 white British
100 individual genetic data files was downloaded from the LDAK website

101 (<https://dougspeed.com/pre-computed-tagging-files/>), and the cutoff was set to 0.01 to preclude
102 large-effect loci that explain at least 1% of phenotypic variance.

103

104 **Mendelian randomization**

105 Mendelian randomization (MR) analysis between two traits was performed to determine whether
106 genetic correlations were due to a causal link or confounding factors using the R package
107 TwoSampleMR³⁵ which encompasses five MR methods (MR Egger, Weighted median, Inverse
108 variance weighted, Simple mode, Weighted mode). The instruments for each exposure trait were
109 significant SNPs (P -value $< 5 \times 10^{-8}$) after clumping, while the instruments for each outcome
110 trait were all SNPs. Variants without SNP ID were annotated using the dbSNP³⁶ database;
111 otherwise, SNPs were removed during subsequent analyses.

112

113 **Epidemiological analyses based on UK Biobank (UKBB) cohort**

114 The UKBB is a large-scale cohort that recruited half a million UK participants (aged 37–73 years)
115 between 2006 and 2010, and was followed up to 2021. Among the 502,412 participants, we
116 excluded those who were pregnant ($n = 379$), lost to follow-up ($n = 1,298$), and had a mismatch
117 between self-reported sex and genetic sex ($n = 371$), or missing information concerning covariates
118 at baseline ($n = 58,637$). Overall, 441,727 participants were included in the study. AMD (ICD10:
119 H35.3; ICD9: 362.5), cataract (ICD10: H25-H28; ICD9: 366), and glaucoma (ICD10: H40.1,
120 H40.8, H40.9; ICD9: 365.1, 365.9) were ascertained based on information from self-reports,
121 primary care records, hospital admissions, and death records. Multivariate Cox regression with
122 separate models for incident AMD, cataract, and glaucoma was used to evaluate pairwise

123 associations among them. In subsequent analyses, multi-state models were used to examine the
124 role of one of the three ocular diseases in the transition between the start of follow-up and the
125 other two disorders. In all models, we adjusted for sex, age, ethnicity, Townsend deprivation index,
126 education level, smoking status, drinking status, physical activity, screen time-based sedentary
127 behavior, diabetes, and other eye problems. This research was conducted using the UKBB
128 resource under application number 83974.

129

130 **Determination of pleiotropic regions**

131 We performed pleiotropic region analysis using gwas-pw³⁷, a tool for jointly analyzing pairs of
132 GWAS traits. Overlapping SNPs of both traits were split into multiple blocks based on the bed
133 files available at <https://bitbucket.org/nygcresearch/ldetect-data>. Separately, gwas-pw reckoned the
134 posterior probability of the four models that the pleiotropic region 1) only associated with
135 phenotype 1, 2) only associated with phenotype 2, 3) associated with both phenotypes, and 4)
136 associated with both phenotypes independently.

137

138 **Identification of pleiotropic loci**

139 To identify pleiotropic variants and characterize pleiotropy at single-variant level, cross-trait
140 meta-analyses were carried out with GWAS summary statistics of three ocular diseases using three
141 different approaches: 1) ASSET³⁸, 2) METAL³⁹, and 3) pleioFDR⁴⁰. ASSET explored all
142 possible subsets of traits and evaluated a fixed-effect meta-analysis for each subset. The default
143 scheme was selected when executing METAL with the correction of sample overlap. pleioFDR
144 leveraged overlapping SNP associations of related phenotypes to identify genetic pleiotropic loci.

145 All significant SNPs involving two or more traits were retained for the following analysis. Once
146 classified, we conducted variant clumping through PLINK ⁴¹ and merged the pleiotropic loci if
147 they physically overlapped ($\pm 250\text{kb}$). The summary statistics of these diseases were standardized
148 using a downloaded reference derived from genome files for 22 autosomes of filtered the 1000
149 Genomes project ⁴² European ancestry samples.

150

151 **Causal cell type estimation**

152 We applied MAGMA ⁴³ to evaluate whether specific ocular cell types showed significant
153 heritability enrichment for traits based on ASSET one-sided summary statistics. MAGMA also
154 requires gene average expression level across cell types derived from single-cell RNA sequencing
155 (scRNA-seq) and single-cell multi-omics sequencing data of anterior chamber angle or
156 retina/choroid ^{20; 21; 23; 44-46} (**Table S2**). We additionally downloaded the raw data and determined
157 the average expression values per cell type for each dataset using Cell Ranger ⁴⁷ and the R
158 package Seurat ⁴⁸ unless the information was available. Cell types were assigned with the gene
159 marker mentioned in the original publications, and the same cell types were manually renamed to
160 maintain concordance with different scRNA-seq data. Gene names were transferred to Entrez gene
161 IDs using the R package biomaRt ⁴⁹. We appointed the direction of testing to “greater” and
162 selected the condition-hide modifier for cell-type trait association analysis. We then leveraged the
163 open chromatin peaks of retinal cell types from single-cell multiome to estimate LD scores for
164 LDSC and conducted an additional cell-type trait association analysis.

165

166 **Causal SNP identification at pleiotropic loci**

167 Colocalization analysis between two-eye eQTL data^{19,50} and ASSET one-sided GWAS data was
168 conducted using the R package COLOC⁵¹. We selected SNPs with an H4 posterior probability >
169 0.75, GWAS P-value < 1×10^{-6} , and eQTL P-value < 0.05 as pleiotropic loci. By utilizing three
170 sets of retina sample Assay of Transposase Accessible Chromatin sequencing (ATAC-seq) and
171 H3K27ac Chromatin immunoprecipitation followed by sequencing (ChIP-seq) data⁵², genomic
172 enhancer regions of the retina were predicted using the Activity-by-Contact (ABC) model⁵³ with
173 default threshold settings. Next, we profiled the causal SNPs through fine-mapping analysis of
174 pleiotropic loci identified by the above three meta-analysis methods. The one-sided ASSET
175 meta-analysis results of pleiotropic SNPs located in the ± 1 Mb region of lead SNPs were
176 imported into PolyFun⁵⁴ for fine-mapping with an embedded statistical method termed Susie⁵⁵,
177 and 95% credible sets were revealed, assuming one causal SNP per locus. SNPs were included in
178 the credible sets until the sum of the posterior probabilities was > 0.95.

179

180 **Pleiotropic causal gene prioritization**

181 The causal genes in a pleiotropic locus were confined to the following rules: 1) Does the locus
182 contain eye eQTL SNPs? If yes, eQTL harboring genes (eGenes) were selected. 2) Is the locus
183 located in the open chromatin peaks from retina H3K27ac HiChIP data²³? If yes, causal genes
184 were anchor-targeted genes. 3) Does the locus have a genomic region overlapping with the ABC
185 model enhancer regions or a cell type-specific peak? If so, the causal genes were enhancer target
186 genes or peak-inclusive genes. 4) If the pleiotropic locus contained none of the eQTL SNPs or was
187 not mapped within any enhancer regions or peaks, the nearest gene with the highest COLOC
188 posterior probability was identified as a causal gene. Moreover, gene ontology (GO) pathway

189 enrichment analysis of causal genes with no more than 10 interactors was conducted in STRING
190 ⁵⁶ to shed light on pathogenic biological processes, and gene-phenotype association analysis was
191 conducted using Enrichr ⁵⁷.

192

193 **Drug repurposing analysis**

194 We curated approved drugs targeted at pleiotropic causal genes and target genes of such drugs for
195 AMD, cataract, and glaucoma from Drugbank ⁵⁸ and DGIdb ⁵⁹ to verify whether the risk genes
196 were identical to the drug target genes. Protein-protein interaction (PPI) network information was
197 obtained from STRING and depicted using Cytoscape ⁶⁰ to evaluate potential relationships
198 between pleiotropic causal genes and drug target genes.

199

200 **Results**

201 **Genetic sharing among AMD, cataract, and glaucoma**

202 To delineate the shared genetic architecture among the three age-related ocular disorders, we first
203 collected full GWAS summary statistics of AMD, cataract, and glaucoma from the latest public
204 resources, incorporating three AMD GWASs, three cataract GWASs and two glaucoma GWASs,
205 and most of them had sample size over 100,000 individuals (**Table S1**). Considering the signal
206 overlaps of the three largest ocular GWAS summary statistics (**Figure S1A**), genetic correlations
207 were measured using LDSC ³³ and SumHer LDK-Thin ³⁴ models. Following careful quality
208 control, we observed moderate and concordant genome-wide genetic correlations among these
209 traits (**Figure 1A, 1B, Figure S1B**), in which glaucoma-cataract and AMD-cataract showed
210 positive genetic correlations, while AMD-glaucoma exhibited negative genetic correlations. This

211 is consistent with a previous study wherein the negative genetic correlation between AMD and
212 glaucoma was reported¹⁶. In addition, multiple bidirectional MR methods were applied to each
213 pair of diseases to assess whether shared genetic components were coherent with true pleiotropy
214 or mediated pleiotropy. Presuming that consistent results in three of the five MR methods indicate
215 a strong causal effect between the two traits, there was no or weak evidence for potentially causal
216 relationships among AMD, cataract, and glaucoma (**Figure S2**).

217

218 **Epidemiological associations among AMD, cataract, and glaucoma**

219 To test whether the pattern of genetic sharing for the three age-related ocular disorders is
220 supported by epidemiological associations, we leveraged 441,727 selected participants from the
221 UKBB with rich information regarding self-reports, primary care records, hospital admissions, and
222 death records. In the UKBB cohort, at the end of follow-up, 36,5471 (82.74%) participants had no
223 AMD, cataract, or glaucoma; 5,611 (1.27 %) had AMD alone; 48,639 (11.01%) had cataract alone;
224 7,431 (1.68%) had glaucoma alone; 8,251 (1.87%) had both AMD and cataract; 1,329 (0.30%) had
225 both AMD and glaucoma; 7,015 (1.59%) had both cataract and glaucoma; and 1,010 (0.23%) had
226 AMD, cataract, and glaucoma. Hazard ratios (HRs) estimated by Cox regression were
227 significantly larger than 1 (P-value < 0.001), which indicated positive correlations among these
228 traits (**Figure 1A, Figure S3**). These results showed significant pairwise associations between
229 AMD, cataract, and glaucoma. Similar results were observed in further analyses using multi-state
230 models which also uncovered positive correlations between cataract and other diseases as genetic
231 correlation analysis showed. The correlation between AMD and glaucoma was inconsistent with
232 our genetic correlation results which may due to environmental effects or inadequate power.

233 Additionally, multi-state models distinguished the roles of one of the three prevalent ocular
234 diseases in the temporal trajectories of the other two. Prevalent glaucoma was inversely associated
235 with AMD after cataract with HR of 0.74 (95% CI: 0.64-0.86), but not with cataract after AMD
236 (**Figure 1C**). Multi-state analyses also showed that the associations of prevalent cataracts with the
237 transition from the start of follow-up to subsequent AMD or subsequent glaucoma were stronger
238 than those with the transition from AMD to glaucoma or from glaucoma to AMD (**Figure 1D**).
239 Accounting for prevalent AMD in transitions of cataract and glaucoma, there was no evidence of
240 stronger associations between prevalent AMD and transitions to cataract after having had
241 glaucoma, or glaucoma after having had cataract (**Figure 1E**). Taken together, these new findings
242 based on genetic evidence and epidemiological associations suggested a latent correlation among
243 age-related ocular traits.

244

245 **Cross-disorder meta-analysis reveals ten pleiotropic loci**

246 Considering the indication for genetic relationships between AMD-cataract, AMD-glaucoma, and
247 cataract-glaucoma, 11 likely pleiotropic regions (posterior probability associated with two
248 phenotypes > 0.6) were identified in the disease pairs using $gwas-pw$ ³⁷, one of which
249 (chr9:20464018-2220526) turned out to be significant of two disease pairs (**Figure 1F, Table S3**).
250 Next, we leveraged the largest collected GWAS summary statistics for AMD, cataract, and
251 glaucoma containing 257,718 cases and 560,421 controls of European ancestry in total (AMD:
252 14,034 cases and 91,214 controls, cataract: 11,306 cases and 349,888 controls, glaucoma: 232,378
253 cases and 119,319 controls), and conducted cross-trait meta-analyses using three complementary
254 methods including ASSET³⁸, METAL³⁹ and pleioFDR⁴⁰. Only those SNPs that surpassed

255 genome-wide significance (P -value $< 5 \times 10^{-8}$) and had influences on at least two traits were
256 reserved. For ASSET, two patterns were supported, and both were performed such that the
257 one-sided ASSET meta-analysis maximized the standard fixed-effect meta-analysis test statistics
258 over all possible subsets and guaranteed the identification of pleiotropic loci that have associations
259 in the same direction, while the two-sided ASSET meta-analysis was performed in two directions
260 automatically. Accordingly, we identified 5, 10, 15, and 7 pleiotropic loci using METAL,
261 one-sided ASSET, two-sided ASSET, and pleioFDR, respectively, under the condition that the
262 genomic inflation factor did not considerably deviate from one (**Figure 2A, Figure S4, Figure**
263 **S5**).

264

265 By guaranteeing that the lead SNPs should be marginally significant in all primary GWAS
266 summary statistics, ten loci were conservatively prioritized as candidate pleiotropic loci for which
267 the one-sided ASSET results overlapped with the other three approaches (**Table 1**). Among these
268 pleiotropic loci, most signals were significantly associated with glaucoma, and were even stronger
269 after meta-analysis although they were weaker in other diseases. Notably, four novel loci (lead
270 SNPs: rs3766916, rs17421627, rs11018564, rs146447071) became significant as the sample size
271 increased. Besides, we found that four candidate pleiotropic loci intersected the aforementioned
272 pleiotropic regions identified by gwas-pw (chr5:87390784-88891173, chr9:20464018-2220526,
273 chr11:87430571-89208854, chr15:110336875-113261782) (**Table 1, Figure 1F**), which rendered
274 our results convincing. Furthermore, we collected additional GWAS datasets of AMD, cataract,
275 and glaucoma from FinnGen project³² and conducted a meta-analysis with ASSET, four loci (lead
276 SNPs: rs12670840, rs944801, rs1619882, and rs1129038) were replicated if the P -value of any

277 SNPs in the same loci was smaller than 1×10^{-5} in one-sided ASSET or two-sided ASSET
278 results.

279

280 **Single-cell multi-omics data integration identifies likely causal cell types of ocular** 281 **comorbidity**

282 To understand the causal disease mechanisms underlying these pleiotropic loci, we investigated
283 which cell types are essential during the development of ocular comorbidity. We obtained six
284 scRNA-seq datasets and a single-cell multiome dataset derived from 33 human eyes (**Table S2**)
285 and performed cell-type trait association analysis to explore the most likely causal cell types
286 whose gene or epigenomic signatures correlate with genetic pleiotropy. In total, more than 40 cell
287 types across the anterior chamber angle and retina/choroid were used in our study. Consequently,
288 Müller cells and astrocytes were concordantly estimated to be two causal cell types of ocular
289 disease susceptibility using both MAGMA and LDSC (**Figure 2B, Figure S6, Table S4, Table**
290 **S5**), suggesting that the two cell types could play a critical role in modulating ocular comorbidity.
291 In addition, vascular endothelium and fibroblasts also displayed significant results in two or more
292 MAGMA analyses (FDR < 0.05), which is consistent with previous study²⁰.

293

294 **Functional prioritization of causal pleiotropic variants and their target genes**

295 To identify the causal genes acting on genetic pleiotropy across the three age-related ocular
296 disorders,
297 we first leveraged PolyFun⁵⁴ to fine-map the ten pleiotropic loci and identified causal variants in
298 the 95% credible sets. We conducted colocalization analysis involving the ten pleiotropic loci

299 based on two retinal *cis*-eQTL datasets^{19;50}, yielding a credible variant rs3766916 colocalizing at
300 several eGenes, including *TRIM46* and *GON4L* (**Figure 2C, Figure S7, Table S6**). *TRIM46*
301 encodes a protein of the tripartite motif family that controls neuronal polarity and
302 high-glucose-induced ferroptosis in human retinal capillary endothelial cells⁶¹, which suggests a
303 potential causal role for retina-associated ocular traits.

304

305 Second, we collected retina H3K27ac HiChIP loops²³ to annotate all credible variants with
306 spatially proximal genes. We found that three credible variants supported by HiChIP loops linked
307 to different genes, and they were located in the eye enhancer regions or Müller cell/astrocyte open
308 chromatin peaks according to single-cell multiome profiles. Notably, we found the SNP rs4845712
309 in high LD with rs3766916 ($r^2 = 0.95$ in European) may be more likely to be the causal SNP at the
310 corresponding pleiotropic locus. rs4845712 in the intron of *EFNA4* gene received the highest
311 posterior probability of fine-mapping analysis and overlapped with a retina H3K27ac HiChIP loop
312 (**Figure 2D**). rs4845712 host gene *EFNA4* has been reported to inhibit axonal regeneration and
313 regulate axon guidance in the optic nerve^{62; 63}, and its HiChIP target gene *CKS1B* encodes a
314 protein that binds to the catalytic subunit of cyclin-dependent kinases, and proliferation and
315 migration of retinoblastoma cells can be inhibited by suppressing the expression of *CKS1B*⁶⁴.
316 Another top credible SNP rs351973, close to *PTBP1* promoter region, can interact with the
317 genomic region containing *KISS1R*, *R3HDM4*, and *ARID3A* genes (**Figure 3A**). Among these
318 genes, knockdown of *Ptbp1* in mice effectively induces the conversion of Müller glia into retinal
319 ganglion cells (RGCs), resulting in alleviation of disease symptoms pertinent to RGC loss⁶⁵.

320

321 Additionally, we applied ABC model⁵³ on ATAC-seq and H3K27ac ChIP-seq data from three
322 retinal samples to predict enhancer-promoter interactions (**Table S7**). Based on the predicted
323 interactions, target genes were achieved for an additional credible variant rs10898526. The SNP
324 rs10898526 located at a pleiotropic locus prioritized by three meta-analysis methods and obtained
325 Müller cell/astrocyte-specific open chromatin signatures. Target gene analysis based on ABC
326 model suggested rs10898526 could interact with *ME3* gene promoter (**Figure 3B**). We found *ME3*
327 was documented to involve in the oxidative decarboxylation of malate to pyruvate and associated
328 with macular thickness⁶⁶. Finally, for other credible variants without evidence of active chromatin
329 marks or chromosome interactions, we annotated the nearest gene as the target gene for the top
330 credible variant at the pleiotropic locus. The annotated and prioritized causal variants and their
331 genes were shown in **Table S8**.

332

333 **Shared biological pathways and drug repurposing opportunities**

334 To assess the pleiotropic causal genes that affect biological pathways relevant to ocular diseases
335 and explore the potential role of candidate genes in drug repurposing, we conducted several
336 functional investigations. GO pathway analysis was first conducted in three orthogonal ontologies
337 to explore the biological mechanisms of causal genes on ocular comorbidity. We detected 47
338 significant (FDR < 0.05) pathways, including the regulation of nerve development (GO:0021675,
339 GO:0007409, and GO:0048666) (**Figure 4A, 4B, Table S9**). Multiple protein modification
340 pathways were also enriched, such as regulation of the protein modification process
341 (GO:0031399), protein phosphorylation (GO:0006468), and histone h3 acetylation (GO:0043966).
342 In addition, *EFNA3*, *EFNA4*, and *SHC1* were hub genes in the PPI network of causal genes

343 **(Figure 4B)**. We conducted gene-phenotype relationship analysis and revealed causal gene set was
344 enriched for skin/hair/eye pigmentation (q-value = 0.0236) and eye color (q-value = 0.0008). We
345 then linked genes to licensed drugs and found aspirin and zopiclone targeted the causal genes *ME3*
346 and *GABRA5* separately. By searching the approved drugs and drug targets for AMD, cataract, and
347 glaucoma in Drugbank⁵⁸ and DGIdb⁵⁹, we identified 88 drug targets for the ocular diseases and
348 found 12 (40%) of the 30 causal genes interacting with these drug targets. Noteworthy, *EFNA4*, a
349 gene identified as being involved in neuronal development in previous pathway analysis,
350 interacted with aflibercept-targeted gene *VEGFA* and pilocarpine-targeted gene *NTRK1* in the PPI
351 network of AMD and glaucoma **(Figure 4C, Figure 4D)**, indicating the drug repurposing
352 opportunities for the treatment of ocular comorbidity.

353

354 **Discussion**

355 In our study, we comprehensively investigated genetic sharing and epidemiological associations
356 for three age-related ocular disorders. We confirmed the significant relationships among AMD,
357 cataract, and glaucoma using a large-scale prospective observational study, genetic correlation
358 analysis, and MR, followed by pleiotropic region analysis to explore regional pleiotropy. Ten
359 significant pleiotropic loci of AMD, cataract, and glaucoma were identified using complementary
360 meta-analyses, four of which achieved a marginally significant threshold in replication
361 meta-analysis. In addition, we identified Müller cells and astrocytes as disease-associated cell
362 types by single-cell multi-omics analysis. By incorporating statistical fine-mapping, retinal eQTL
363 colocalization, and 3D genome loop data, we systematically prioritized causal target genes for
364 pleiotropic variants. The interrogation of network biology was also implemented to identify

365 disease genes-associated molecules and pathways for potential drug repositioning of ocular
366 disorders.

367

368 To our knowledge, no previous study has investigated the genetic and non-genetic associations
369 among AMD, cataract, and glaucoma. Several observational, clinical, and genetic evidence
370 strongly suggest a shared biological basis or similar pathophysiological mechanisms among these
371 age-related ocular disorders^{2-4; 16}. In this study, both epidemiological evidence based on
372 large-scale UKBB data and genetic evidence based on several largest GWASs data supported
373 pairwise tight associations between AMD, cataract, and glaucoma at different levels. The
374 mechanisms behind our findings will shed light on the in-depth investigation of gene-environment
375 interactions and comorbidity mechanisms across AMD, cataract, and glaucoma, which could also
376 initiate further ocular disease comorbidity studies and emphasize the importance of
377 comprehensive diagnosis and disease prevention in clinical practice.

378

379 By cross-disease meta-analysis at both variant and locus levels, we successfully identified ten
380 pleiotropic loci. Nevertheless, understanding disease-causal cell types is of great value for the
381 investigation of the precise mechanism between these loci-influenced genes and disease
382 pathogenesis. We identified Müller cells and astrocytes as potential casual cell types for ocular
383 comorbidity using two algorithms. A study claimed that Müller cells play a role in
384 regulating serine biosynthesis, a critical part of the macular defense against oxidative stress, and
385 their dysregulation may cause macular lesions⁶⁷. Furthermore, Müller cells and astrocytes have
386 multiple functions symbiotically associated with RGCs, such as glutamate clearance, neurotrophic

387 factor release, and neurotransmitter recycling⁶⁸, and the abnormality of RGCs will cause the
388 impairment of visual acuity. Another study reported that the loss of astrocytes, together with
389 retinal ischemia that occurs in AMD macula, could induce the death of RGCs owing to the
390 oxidative damage⁶⁹. Despite insufficient evidence in our study, a connection between macular
391 vascular endothelium and these ocular diseases has been widely discussed^{44; 70-73}. As a matrix cell
392 type, fibroblasts can be activated by matricellular proteins, resulting in abnormal fibrotic processes
393 in the extracellular matrix and subsequent elevated intraocular pressure⁷⁴. In addition, fibroblasts
394 may be recruited to neovascular lesions and differentiate into myofibroblasts, a key cell type in
395 macular fibrosis secondary to neovascular AMD⁷⁵.

396

397 Leveraging pleiotropic genes we found, we nominated several ocular disease-related pathways
398 like the regulation of nerve development. The optic nerve is made up of RGC axons and transmits
399 visual signals from photoreceptor cells to the brain. Diminution of vision will occur once the
400 transitions were hindered. Glaucoma is a neurodegenerative disorder manifesting selective,
401 progressive, and irreversible degeneration of the optic nerve, and optic nerve regeneration in
402 glaucoma treatment was widely studied⁷⁶⁻⁷⁸. The photoreceptor synapses across retinas of patients
403 with AMD retract into the outer nuclear layer which evokes the subsequent outgrowth and
404 reformation of synaptic contacts⁷⁹. Besides, optic nerve edema was found weeks to months after
405 cataract extraction⁸⁰. By conducting gene-phenotype relationship analysis, pleiotropic genes were
406 related to eye color, which suggested the relevance to these age-related ocular diseases. Darker iris
407 color is pertinent with increased risks of cataract and intraocular pressure and mitigated risks of
408 AMD, uveal melanoma, and pigmentary glaucoma^{14; 81-84}.

409

410 There are a few shortcomings in these analyses. First, the relationship between AMD and
411 glaucoma was not consistent between genetic correlation analysis and epidemiological evidence
412 which may be due to environmental impact factors. More studies should be conducted to clarify
413 the relationship between AMD and glaucoma. Second, the number of glaucoma cases was much
414 larger than those for the other two diseases, and some controls may inevitably overlap in glaucoma
415 and cataract, which may affect the power of signals and cause systemic errors and wrongly
416 preferential shared effect in meta-analysis. Third, in the present study, we found several cell types
417 related to these traits, however, based on limited public annotation data, tissue-level annotation
418 profiles were leveraged rather than cell type-specific data to identify truly causal genes. Thus,
419 genetic information regarding the eye needs to be interpreted more precisely and accurately.
420 Fourth, our fine-mapping only yielded credible sets of variants under the assumption of one causal
421 variant; therefore, the prioritized causal genes may be underestimated. In addition, although we
422 found several signs connecting certain drug targets and causal pleiotropic genes, whether these
423 drugs are beneficial or harmful to the phenotype is still unknown. Further experiments concerning
424 drug discovery and repurposing need to be conducted in the future.

425

426 **Declaration of interests**

427 The authors declare no conflict of interest.

428

429 **Acknowledgments**

430 This study was supported by the National Natural Science Foundation of China (Grant Numbers

431 82020108007, 81830026, 32070675) and the Beijing-Tianjin-Hebei Special Project [Grant
432 Number 19JCZDJC64300(Z), 20JCZXJC00180].

433

434 **Author contributions**

435 H.Y. and M.J.L. conceived of the project. X.Y., H.Y., and Y.J. performed the analyses. H.H., X.K.,
436 and M.L. contributed to the data collection and processing. Y.Z., J.W., and X.F. contributed to
437 manuscript polishing and provided analysis suggestions. X.Y., M.J.L., and H.Y. wrote the
438 manuscript. The authors read and approved the final submission.

439

440 **Data and code availability**

441 The published article includes all datasets analyzed during this study.

442 **Reference**

- 443 1. (2021). Trends in prevalence of blindness and distance and near vision impairment over 30
444 years: an analysis for the Global Burden of Disease Study. *The Lancet Global health* 9,
445 e130-e143.
- 446 2. Vinod, K., Gedde, S.J., Feuer, W.J., Panarelli, J.F., Chang, T.C., Chen, P.P., and Parrish,
447 R.K., 2nd. (2017). Practice Preferences for Glaucoma Surgery: A Survey of the
448 American Glaucoma Society. *Journal of glaucoma* 26, 687-693.
- 449 3. Hu, C.C., Ho, J.D., Lin, H.C., and Kao, L.T. (2017). Association between open-angle
450 glaucoma and neovascular age-related macular degeneration: a case-control study.
451 *Eye (London, England)* 31, 872-877.
- 452 4. Weill, Y., Hanhart, J., Zadok, D., Smadja, D., Gelman, E., and Abulafia, A. (2021). Patient
453 management modifications in cataract surgery candidates following incorporation of
454 routine preoperative macular optical coherence tomography. *J Cataract Refract Surg*
455 47, 78-82.
- 456 5. Fritsche, L.G., Igl, W., Bailey, J.N., Grassmann, F., Sengupta, S., Bragg-Gresham, J.L.,
457 Burdon, K.P., Hebbring, S.J., Wen, C., Gorski, M., et al. (2016). A large genome-wide
458 association study of age-related macular degeneration highlights contributions of rare
459 and common variants. *Nat Genet* 48, 134-143.
- 460 6. Winkler, T.W., Grassmann, F., Brandl, C., Kiel, C., Gunther, F., Strunz, T., Weidner, L.,
461 Zimmermann, M.E., Korb, C.A., Poplawski, A., et al. (2020). Genome-wide association
462 meta-analysis for early age-related macular degeneration highlights novel loci and
463 insights for advanced disease. *BMC Med Genomics* 13, 120.

- 464 7. Choquet, H., Melles, R.B., Anand, D., Yin, J., Cuellar-Partida, G., Wang, W., and Me
465 Research, T., Hoffmann, T.J., Nair, K.S., Hysi, P.G., et al. (2021). A large multiethnic
466 GWAS meta-analysis of cataract identifies new risk loci and sex-specific effects. *Nat*
467 *Commun* 12, 3595.
- 468 8. Khawaja, A.P., Cooke Bailey, J.N., Wareham, N.J., Scott, R.A., Simcoe, M., Igo, R.P., Jr.,
469 Song, Y.E., Wojciechowski, R., Cheng, C.Y., Khaw, P.T., et al. (2018). Genome-wide
470 analyses identify 68 new loci associated with intraocular pressure and improve risk
471 prediction for primary open-angle glaucoma. *Nat Genet* 50, 778-782.
- 472 9. Gharahkhani, P., Jorgenson, E., Hysi, P., Khawaja, A.P., Pendergrass, S., Han, X., Ong,
473 J.S., Hewitt, A.W., Segre, A.V., Rouhana, J.M., et al. (2021). Genome-wide
474 meta-analysis identifies 127 open-angle glaucoma loci with consistent effect across
475 ancestries. *Nat Commun* 12, 1258.
- 476 10. Mackey, D.A., and Hewitt, A.W. (2014). Genome-wide association study success in
477 ophthalmology. *Curr Opin Ophthalmol* 25, 386-393.
- 478 11. Seddon, J.M., Cote, J., Page, W.F., Aggen, S.H., and Neale, M.C. (2005). The US twin
479 study of age-related macular degeneration: relative roles of genetic and environmental
480 influences. *Arch Ophthalmol* 123, 321-327.
- 481 12. Hammond, C.J., Snieder, H., Spector, T.D., and Gilbert, C.E. (2000). Genetic and
482 environmental factors in age-related nuclear cataracts in monozygotic and dizygotic
483 twins. *N Engl J Med* 342, 1786-1790.
- 484 13. Yonova-Doing, E., Forkin, Z.A., Hysi, P.G., Williams, K.M., Spector, T.D., Gilbert, C.E., and
485 Hammond, C.J. (2016). Genetic and Dietary Factors Influencing the Progression of

- 486 Nuclear Cataract. *Ophthalmology* 123, 1237-1244.
- 487 14. Simcoe, M.J., Weisschuh, N., Wissinger, B., Hysi, P.G., and Hammond, C.J. (2020).
- 488 Genetic Heritability of Pigmentary Glaucoma and Associations With Other Eye
- 489 Phenotypes. *JAMA ophthalmology* 138, 294-299.
- 490 15. van Koolwijk, L.M., Despriet, D.D., van Duijn, C.M., Pardo Cortes, L.M., Vingerling, J.R.,
- 491 Aulchenko, Y.S., Oostra, B.A., Klaver, C.C., and Lemij, H.G. (2007). Genetic
- 492 contributions to glaucoma: heritability of intraocular pressure, retinal nerve fiber layer
- 493 thickness, and optic disc morphology. *Investigative ophthalmology & visual science* 48,
- 494 3669-3676.
- 495 16. Grassmann, F., Kiel, C., Zimmermann, M.E., Gorski, M., Grassmann, V., Stark, K.,
- 496 International, A.M.D.G.C., Heid, I.M., and Weber, B.H. (2017). Genetic pleiotropy
- 497 between age-related macular degeneration and 16 complex diseases and traits.
- 498 *Genome Med* 9, 29.
- 499 17. Cuellar-Partida, G., Craig, J.E., Burdon, K.P., Wang, J.J., Vote, B.J., Souzeau, E.,
- 500 McAllister, I.L., Isaacs, T., Lake, S., Mackey, D.A., et al. (2016). Assessment of
- 501 polygenic effects links primary open-angle glaucoma and age-related macular
- 502 degeneration. *Scientific reports* 6, 26885.
- 503 18. Xue, Z., Yuan, J., Chen, F., Yao, Y., Xing, S., Yu, X., Li, K., Wang, C., Bao, J., Qu, J., et al.
- 504 (2022). Genome-wide association meta-analysis of 88,250 individuals highlights
- 505 pleiotropic mechanisms of five ocular diseases in UK Biobank. *EBioMedicine* 82,
- 506 104161.
- 507 19. Ratnapriya, R., Sosina, O.A., Starostik, M.R., Kwicklis, M., Kappahn, R.J., Fritsche, L.G.,

- 508 Walton, A., Arvanitis, M., Gieser, L., Pietraszkiewicz, A., et al. (2019). Retinal
509 transcriptome and eQTL analyses identify genes associated with age-related macular
510 degeneration. *Nature genetics* 51, 606-610.
- 511 20. Orozco, L.D., Chen, H.H., Cox, C., Katschke, K.J., Jr., Arceo, R., Espiritu, C., Caplazi, P.,
512 Nghiem, S.S., Chen, Y.J., Modrusan, Z., et al. (2020). Integration of eQTL and a
513 Single-Cell Atlas in the Human Eye Identifies Causal Genes for Age-Related Macular
514 Degeneration. *Cell reports* 30, 1246-1259.e1246.
- 515 21. Menon, M., Mohammadi, S., Davila-Velderrain, J., Goods, B.A., Cadwell, T.D., Xing, Y.,
516 Stemmer-Rachamimov, A., Shalek, A.K., Love, J.C., Kellis, M., et al. (2019).
517 Single-cell transcriptomic atlas of the human retina identifies cell types associated with
518 age-related macular degeneration. *Nat Commun* 10, 4902.
- 519 22. Wang, J., Zibetti, C., Shang, P., Sripathi, S.R., Zhang, P., Cano, M., Hoang, T., Xia, S., Ji,
520 H., Merbs, S.L., et al. (2018). ATAC-Seq analysis reveals a widespread decrease of
521 chromatin accessibility in age-related macular degeneration. *Nature communications*
522 9, 1364.
- 523 23. Wang, S.K., Nair, S., Li, R., Kraft, K., Pampari, A., Patel, A., Kang, J.B., Luong, C.,
524 Kundaje, A., and Chang, H.Y. (2022). Single-cell multiome of the human retina and
525 deep learning nominate causal variants in complex eye diseases. *bioRxiv*,
526 2022.2003.2009.483684.
- 527 24. Buniello, A., MacArthur, J.A.L., Cerezo, M., Harris, L.W., Hayhurst, J., Malangone, C.,
528 McMahon, A., Morales, J., Mountjoy, E., Sollis, E., et al. (2019). The NHGRI-EBI
529 GWAS Catalog of published genome-wide association studies, targeted arrays and

- 530 summary statistics 2019. *Nucleic acids research* 47, D1005-d1012.
- 531 25. Sudlow, C., Gallacher, J., Allen, N., Beral, V., Burton, P., Danesh, J., Downey, P., Elliott, P.,
532 Green, J., Landray, M., et al. (2015). UK biobank: an open access resource for
533 identifying the causes of a wide range of complex diseases of middle and old age.
534 *PLoS medicine* 12, e1001779.
- 535 26. Canela-Xandri, O., Rawlik, K., and Tenesa, A. (2018). An atlas of genetic associations in
536 UK Biobank. *Nature genetics* 50, 1593-1599.
- 537 27. Watanabe, K., Stringer, S., Frei, O., Umićević Mirkov, M., de Leeuw, C., Polderman, T.J.C.,
538 van der Sluis, S., Andreassen, O.A., Neale, B.M., and Posthuma, D. (2019). A global
539 overview of pleiotropy and genetic architecture in complex traits. *Nature genetics* 51,
540 1339-1348.
- 541 28. Zheng, J., Erzurumluoglu, A.M., Elsworth, B.L., Kemp, J.P., Howe, L., Haycock, P.C.,
542 Hemani, G., Tansey, K., Laurin, C., Pourcain, B.S., et al. (2017). LD Hub: a centralized
543 database and web interface to perform LD score regression that maximizes the
544 potential of summary level GWAS data for SNP heritability and genetic correlation
545 analysis. *Bioinformatics (Oxford, England)* 33, 272-279.
- 546 29. Leslie, R., O'Donnell, C.J., and Johnson, A.D. (2014). GRASP: analysis of
547 genotype-phenotype results from 1390 genome-wide association studies and
548 corresponding open access database. *Bioinformatics (Oxford, England)* 30, i185-194.
- 549 30. Kamat, M.A., Blackshaw, J.A., Young, R., Surendran, P., Burgess, S., Danesh, J.,
550 Butterworth, A.S., and Staley, J.R. (2019). PhenoScanner V2: an expanded tool for
551 searching human genotype-phenotype associations. *Bioinformatics (Oxford, England)*

- 552 35, 4851-4853.
- 553 31. Mailman, M.D., Feolo, M., Jin, Y., Kimura, M., Tryka, K., Bagoutdinov, R., Hao, L., Kiang,
554 A., Paschall, J., Phan, L., et al. (2007). The NCBI dbGaP database of genotypes and
555 phenotypes. *Nature genetics* 39, 1181-1186.
- 556 32. Kurki, M.I., Karjalainen, J., Palta, P., Sipilä, T.P., Kristiansson, K., Donner, K., Reeve, M.P.,
557 Laivuori, H., Aavikko, M., Kaunisto, M.A., et al. (2022). FinnGen: Unique genetic
558 insights from combining isolated population and national health register data. *medRxiv*,
559 2022.2003.2003.22271360.
- 560 33. Bulik-Sullivan, B., Finucane, H.K., Anttila, V., Gusev, A., Day, F.R., Loh, P.R., Duncan, L.,
561 Perry, J.R., Patterson, N., Robinson, E.B., et al. (2015). An atlas of genetic
562 correlations across human diseases and traits. *Nature genetics* 47, 1236-1241.
- 563 34. Zhang, Q., Privé, F., Vilhjálmsson, B., and Speed, D. (2021). Improved genetic prediction
564 of complex traits from individual-level data or summary statistics. *Nature*
565 *communications* 12, 4192.
- 566 35. Hemani, G., Zheng, J., Elsworth, B., Wade, K.H., Haberland, V., Baird, D., Laurin, C.,
567 Burgess, S., Bowden, J., Langdon, R., et al. (2018). The MR-Base platform supports
568 systematic causal inference across the human phenome. *eLife* 7.
- 569 36. Sherry, S.T., Ward, M.H., Kholodov, M., Baker, J., Phan, L., Smigielski, E.M., and Sirotkin,
570 K. (2001). dbSNP: the NCBI database of genetic variation. *Nucleic acids research* 29,
571 308-311.
- 572 37. Pickrell, J.K., Berisa, T., Liu, J.Z., Séguérel, L., Tung, J.Y., and Hinds, D.A. (2016).
573 Detection and interpretation of shared genetic influences on 42 human traits. *Nature*

- 574 genetics 48, 709-717.
- 575 38. Bhattacharjee, S., Rajaraman, P., Jacobs, K.B., Wheeler, W.A., Melin, B.S., Hartge, P.,
576 Yeager, M., Chung, C.C., Chanock, S.J., and Chatterjee, N. (2012). A subset-based
577 approach improves power and interpretation for the combined analysis of genetic
578 association studies of heterogeneous traits. *American journal of human genetics* 90,
579 821-835.
- 580 39. Willer, C.J., Li, Y., and Abecasis, G.R. (2010). METAL: fast and efficient meta-analysis of
581 genomewide association scans. *Bioinformatics (Oxford, England)* 26, 2190-2191.
- 582 40. Andreassen, O.A., Thompson, W.K., Schork, A.J., Ripke, S., Mattingsdal, M., Kelsoe, J.R.,
583 Kendler, K.S., O'Donovan, M.C., Rujescu, D., Werge, T., et al. (2013). Improved
584 detection of common variants associated with schizophrenia and bipolar disorder
585 using pleiotropy-informed conditional false discovery rate. *PLoS genetics* 9,
586 e1003455.
- 587 41. Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M.A., Bender, D., Maller, J.,
588 Sklar, P., de Bakker, P.I., Daly, M.J., et al. (2007). PLINK: a tool set for whole-genome
589 association and population-based linkage analyses. *American journal of human*
590 *genetics* 81, 559-575.
- 591 42. Auton, A., Brooks, L.D., Durbin, R.M., Garrison, E.P., Kang, H.M., Korbel, J.O., Marchini,
592 J.L., McCarthy, S., McVean, G.A., and Abecasis, G.R. (2015). A global reference for
593 human genetic variation. *Nature* 526, 68-74.
- 594 43. de Leeuw, C.A., Mooij, J.M., Heskes, T., and Posthuma, D. (2015). MAGMA: generalized
595 gene-set analysis of GWAS data. *PLoS computational biology* 11, e1004219.

- 596 44. Voigt, A.P., Mulfaul, K., Mullin, N.K., Flamme-Wiese, M.J., Giacalone, J.C., Stone, E.M.,
597 Tucker, B.A., Scheetz, T.E., and Mullins, R.F. (2019). Single-cell transcriptomics of
598 the human retinal pigment epithelium and choroid in health and macular degeneration.
599 Proceedings of the National Academy of Sciences of the United States of America 116,
600 24100-24107.
- 601 45. van Zyl, T., Yan, W., McAdams, A., Peng, Y.R., Shekhar, K., Regev, A., Juric, D., and
602 Sanes, J.R. (2020). Cell atlas of aqueous humor outflow pathways in eyes of humans
603 and four model species provides insight into glaucoma pathogenesis. Proceedings of
604 the National Academy of Sciences of the United States of America 117, 10339-10349.
- 605 46. Patel, G., Fury, W., Yang, H., Gomez-Caraballo, M., Bai, Y., Yang, T., Adler, C., Wei, Y., Ni,
606 M., Schmitt, H., et al. (2020). Molecular taxonomy of human ocular outflow tissues
607 defined by single-cell transcriptomics. Proceedings of the National Academy of
608 Sciences of the United States of America 117, 12856-12867.
- 609 47. Zheng, G.X., Terry, J.M., Belgrader, P., Ryvkin, P., Bent, Z.W., Wilson, R., Ziraldo, S.B.,
610 Wheeler, T.D., McDermott, G.P., Zhu, J., et al. (2017). Massively parallel digital
611 transcriptional profiling of single cells. Nature communications 8, 14049.
- 612 48. Hao, Y., Hao, S., Andersen-Nissen, E., Mauck, W.M., 3rd, Zheng, S., Butler, A., Lee, M.J.,
613 Wilk, A.J., Darby, C., Zager, M., et al. (2021). Integrated analysis of multimodal
614 single-cell data. Cell 184, 3573-3587.e3529.
- 615 49. Durinck, S., Spellman, P.T., Birney, E., and Huber, W. (2009). Mapping identifiers for the
616 integration of genomic datasets with the R/Bioconductor package biomaRt. Nature
617 protocols 4, 1184-1191.

- 618 50. Strunz, T., Kiel, C., Grassmann, F., Ratnapriya, R., Kwicklis, M., Karlstetter, M., Fauser, S.,
619 Arend, N., Swaroop, A., Langmann, T., et al. (2020). A mega-analysis of expression
620 quantitative trait loci in retinal tissue. *PLoS genetics* 16, e1008934.
- 621 51. Giambartolomei, C., Vukcevic, D., Schadt, E.E., Franke, L., Hingorani, A.D., Wallace, C.,
622 and Plagnol, V. (2014). Bayesian test for colocalisation between pairs of genetic
623 association studies using summary statistics. *PLoS genetics* 10, e1004383.
- 624 52. Cherry, T.J., Yang, M.G., Harmin, D.A., Tao, P., Timms, A.E., Bauwens, M., Allikmets, R.,
625 Jones, E.M., Chen, R., De Baere, E., et al. (2020). Mapping the cis-regulatory
626 architecture of the human retina reveals noncoding genetic variation in disease.
627 *Proceedings of the National Academy of Sciences of the United States of America* 117,
628 9001-9012.
- 629 53. Fulco, C.P., Nasser, J., Jones, T.R., Munson, G., Bergman, D.T., Subramanian, V.,
630 Grossman, S.R., Anyoha, R., Doughty, B.R., Patwardhan, T.A., et al. (2019).
631 Activity-by-contact model of enhancer-promoter regulation from thousands of CRISPR
632 perturbations. *Nature genetics* 51, 1664-1669.
- 633 54. Weissbrod, O., Hormozdiari, F., Benner, C., Cui, R., Ulirsch, J., Gazal, S., Schoech, A.P.,
634 van de Geijn, B., Reshef, Y., Márquez-Luna, C., et al. (2020). Functionally informed
635 fine-mapping and polygenic localization of complex trait heritability. *Nature genetics*
636 52, 1355-1363.
- 637 55. Wang, G., Sarkar, A., Carbonetto, P., and Stephens, M. (2020). A simple new approach to
638 variable selection in regression, with application to genetic fine mapping. *Journal of*
639 *the Royal Statistical Society: Series B (Statistical Methodology)* 82, 1273-1300.

- 640 56. Szklarczyk, D., Gable, A.L., Lyon, D., Junge, A., Wyder, S., Huerta-Cepas, J., Simonovic,
641 M., Doncheva, N.T., Morris, J.H., Bork, P., et al. (2019). STRING v11: protein-protein
642 association networks with increased coverage, supporting functional discovery in
643 genome-wide experimental datasets. *Nucleic acids research* 47, D607-d613.
- 644 57. Xie, Z., Bailey, A., Kuleshov, M.V., Clarke, D.J.B., Evangelista, J.E., Jenkins, S.L.,
645 Lachmann, A., Wojciechowicz, M.L., Kropiwnicki, E., Jagodnik, K.M., et al. (2021).
646 Gene Set Knowledge Discovery with Enrichr. *Current protocols* 1, e90.
- 647 58. Wishart, D.S., Knox, C., Guo, A.C., Shrivastava, S., Hassanali, M., Stothard, P., Chang, Z.,
648 and Woolsey, J. (2006). DrugBank: a comprehensive resource for in silico drug
649 discovery and exploration. *Nucleic acids research* 34, D668-672.
- 650 59. Freshour, S.L., Kiwala, S., Cotto, K.C., Coffman, A.C., McMichael, J.F., Song, J.J., Griffith,
651 M., Griffith, O.L., and Wagner, A.H. (2021). Integration of the Drug-Gene Interaction
652 Database (DGldb 4.0) with open crowdsourcing efforts. *Nucleic acids research* 49,
653 D1144-d1151.
- 654 60. Shannon, P., Markiel, A., Ozier, O., Baliga, N.S., Wang, J.T., Ramage, D., Amin, N.,
655 Schwikowski, B., and Ideker, T. (2003). Cytoscape: a software environment for
656 integrated models of biomolecular interaction networks. *Genome research* 13,
657 2498-2504.
- 658 61. Zhang, J., Qiu, Q., Wang, H., Chen, C., and Luo, D. (2021). TRIM46 contributes to high
659 glucose-induced ferroptosis and cell growth inhibition in human retinal capillary
660 endothelial cells by facilitating GPX4 ubiquitination. *Experimental cell research* 407,
661 112800.

- 662 62. Goldshmit, Y., Galea, M.P., Wise, G., Bartlett, P.F., and Turnley, A.M. (2004). Axonal
663 regeneration and lack of astrocytic gliosis in EphA4-deficient mice. *The Journal of*
664 *neuroscience : the official journal of the Society for Neuroscience* 24, 10064-10073.
- 665 63. Kozulin, P., Natoli, R., O'Brien, K.M., Madigan, M.C., and Provis, J.M. (2009). Differential
666 expression of anti-angiogenic factors and guidance genes in the developing macula.
667 *Molecular vision* 15, 45-59.
- 668 64. Zeng, Z., Gao, Z.L., Zhang, Z.P., Jiang, H.B., Yang, C.Q., Yang, J., and Xia, X.B. (2019).
669 Downregulation of CKS1B restrains the proliferation, migration, invasion and
670 angiogenesis of retinoblastoma cells through the MEK/ERK signaling pathway.
671 *International journal of molecular medicine* 44, 103-114.
- 672 65. Zhou, H., Su, J., Hu, X., Zhou, C., Li, H., Chen, Z., Xiao, Q., Wang, B., Wu, W., Sun, Y., et
673 al. (2020). Glia-to-Neuron Conversion by CRISPR-CasRx Alleviates Symptoms of
674 Neurological Disease in Mice. *Cell* 181, 590-603.e516.
- 675 66. Francis, P.J. (2011). The influence of genetics on response to treatment with ranibizumab
676 (Lucentis) for age-related macular degeneration: the Lucentis Genotype Study (an
677 American Ophthalmological Society thesis). *Transactions of the American*
678 *Ophthalmological Society* 109, 115-156.
- 679 67. Zhang, T., Zhu, L., Madigan, M.C., Liu, W., Shen, W., Cherepanoff, S., Zhou, F., Zeng, S.,
680 Du, J., and Gillies, M.C. (2019). Human macular Müller cells rely more on serine
681 biosynthesis to combat oxidative stress than those from the periphery. *eLife* 8.
- 682 68. García-Bermúdez, M.Y., Freude, K.K., Mouhammad, Z.A., van Wijngaarden, P., Martin,
683 K.K., and Kolko, M. (2021). Glial Cells in Glaucoma: Friends, Foes, and Potential

- 684 Therapeutic Targets. *Frontiers in neurology* 12, 624983.
- 685 69. Ramírez, J.M., Ramírez, A.I., Salazar, J.J., de Hoz, R., and Triviño, A. (2001). Changes of
686 astrocytes in retinal ageing and age-related macular degeneration. *Experimental eye*
687 *research* 73, 601-615.
- 688 70. Fu, D.J., Keenan, T.D., Faes, L., Lim, E., Wagner, S.K., Moraes, G., Huemer, J., Kern, C.,
689 Patel, P.J., Balaskas, K., et al. (2021). Insights From Survival Analyses During 12
690 Years of Anti-Vascular Endothelial Growth Factor Therapy for Neovascular
691 Age-Related Macular Degeneration. *JAMA ophthalmology* 139, 57-67.
- 692 71. Klein, B.E., Klein, R., Lee, K.E., Knudtson, M.D., and Tsai, M.Y. (2006). Markers of
693 inflammation, vascular endothelial dysfunction, and age-related cataract. *American*
694 *journal of ophthalmology* 141, 116-122.
- 695 72. Bukhari, S.M., Kiu, K.Y., Thambiraja, R., Sulong, S., Rasool, A.H., and Liza-Sharmini, A.T.
696 (2016). Microvascular endothelial function and severity of primary open angle
697 glaucoma. *Eye (London, England)* 30, 1579-1587.
- 698 73. Su, W.W., Cheng, S.T., Ho, W.J., Tsay, P.K., Wu, S.C., and Chang, S.H. (2008).
699 Glaucoma is associated with peripheral vascular endothelial dysfunction.
700 *Ophthalmology* 115, 1173-1178.e1171.
- 701 74. Wallace, D.M., Murphy-Ullrich, J.E., Downs, J.C., and O'Brien, C.J. (2014). The role of
702 matricellular proteins in glaucoma. *Matrix biology : journal of the International Society*
703 *for Matrix Biology* 37, 174-182.
- 704 75. Little, K., Ma, J.H., Yang, N., Chen, M., and Xu, H. (2018). Myofibroblasts in macular
705 fibrosis secondary to neovascular age-related macular degeneration - the potential

- 706 sources and molecular cues for their recruitment and activation. *EBioMedicine* 38,
707 283-291.
- 708 76. Yuan, F., Wang, M., Jin, K., and Xiang, M. (2021). Advances in Regeneration of Retinal
709 Ganglion Cells and Optic Nerves. *International journal of molecular sciences* 22.
- 710 77. You, M., Rong, R., Zeng, Z., Xia, X., and Ji, D. (2021). Transneuronal Degeneration in the
711 Brain During Glaucoma. *Frontiers in aging neuroscience* 13, 643685.
- 712 78. Williams, P.R., Benowitz, L.I., Goldberg, J.L., and He, Z. (2020). Axon Regeneration in the
713 Mammalian Optic Nerve. *Annual review of vision science* 6, 195-213.
- 714 79. Sullivan, R.K., Woldemussie, E., and Pow, D.V. (2007). Dendritic and synaptic plasticity of
715 neurons in the human age-related macular degeneration retina. *Investigative*
716 *ophthalmology & visual science* 48, 2782-2791.
- 717 80. McCulley, T.J. (2012). Ischemic optic neuropathy and cataract extraction: What do I need
718 to know? *Oman journal of ophthalmology* 5, 141-143.
- 719 81. Sun, H.P., Lin, Y., and Pan, C.W. (2014). Iris color and associated pathological ocular
720 complications: a review of epidemiologic studies. *International journal of*
721 *ophthalmology* 7, 872-878.
- 722 82. Mitchell, R., Rochtchina, E., Lee, A., Wang, J.J., and Mitchell, P. (2003). Iris color and
723 intraocular pressure: the Blue Mountains Eye Study. *American journal of*
724 *ophthalmology* 135, 384-386.
- 725 83. McGowan, A., Silvestri, G., Moore, E., Silvestri, V., Patterson, C.C., Maxwell, A.P., and
726 McKay, G.J. (2014). Retinal vascular caliber, iris color, and age-related macular
727 degeneration in the Irish Nun Eye Study. *Investigative ophthalmology & visual science*

728 56, 382-387.

729 84. Frank, R.N., Puklin, J.E., Stock, C., and Canter, L.A. (2000). Race, iris color, and

730 age-related macular degeneration. Transactions of the American Ophthalmological

731 Society 98, 109-115; discussion 115-107.

732

733

734 **Figure legends**

735 **Figure 1. Genetic pleiotropy and epidemiological relationship of the three age-related ocular**
736 **disorders.**

737 **A.** Epidemiological and genetic correlations between AMD, cataract, and glaucoma. Significant
738 and strongest genetic correlations of disparate methods are shown. Red: hazard ratios estimated by
739 Cox regression; blue: genetic correlations estimated by LDSC; yellow: genetic correlations
740 estimated by LDAK. **B.** Genetic correlations of AMD, cataract, and glaucoma estimated by LDSC.
741 The size and color of circles show the genetic correlations of disease pairs and the black stars
742 indicate significant results and. **C.** Multi-state models for the role of glaucoma in transitions to
743 other two diseases. **D.** Multi-state models for the role of cataract in transitions to other two
744 diseases. **E.** Multi-state models for the role of AMD in transitions to other two diseases. **D.**
745 Chromosome graphics showing the pleiotropic regions assessed by gwas-pw. A partial enlarged
746 view shows the pleiotropic region resided in chromosome 9 which overlapped with one locus
747 identified by meta-analysis. Different color dots represent the posterior probability of trait pairs
748 (red: AMD-cataract; blue: AMD-glaucoma; green: cataract-glaucoma). The dashed line represents
749 the predictive threshold of posterior probability > 0.6 .

750 **Figure 2. The pleiotropic loci of ocular phenotypes as well as trait-associated cell types.**

751 **A.** Circular Manhattan plot of the meta-analysis results using one-sided ASSET. The orange
752 triangles denote the lead SNPs of pleiotropic loci identified by three meta-analysis methods. The
753 texts beside triangles show the nearest genes of these loci. The arcs in the outer layer represent
754 chromosome positions and the number of SNPs in each position is depicted with different colors.
755 Each dot in the inner layer represents a SNP and the red circle indicates the genome-wide

756 significant threshold ($P\text{-value} \leq 5 \times 10^{-8}$). **B.** The significance of various cell types from
757 MAGMA and LDSC in the cell-type trait association analysis. The significant cell types after
758 Benjamini-Hochberg correction ($FDR < 0.05$) are highlighted. **C.** Locus-compare plots of lead
759 SNP rs3766916 with macular eQTL gene TRIM46. Different colors of dots represent the linkage
760 disequilibrium between the lead SNP (colored purple) and corresponding SNP. **D.** Locuszoom plots
761 of one-sided ASSET associations and posterior probability of causality for variants around risk
762 SNP rs4845712 which overlaps with *EFNA3* enhancer and retinal H3K27ac HiChIP data. The risk
763 variant is uniquely highlighted with purple and all other SNPs are highlighted by their r^2 . The
764 overlapped open chromatin peaks of 13 retinal cell types are shown in the middle. Anchor regions
765 of the retina are highlighted with an orange or blue rectangle and red arcs show the enhance-gene
766 pairs predicted by Activity-by-Contact model. Genes in red and blue represent the sense and
767 antisense directions, respectively. The dashed line indicated the interested SNP position.

768 **Figure 3. Integration with retinal eQTLs, epigenomic, and 3D genome data for causal genes**
769 **prioritization.**

770 **A.** Locuszoom plots of one-sided ASSET associations and posterior probability of causality for
771 variants around risk SNP rs351973 which reside in one of the HiChIP anchors. **B.** Locuszoom
772 plots of one-sided ASSET associations and posterior probability of causality for variants around
773 risk SNP rs10898526 which overlaps with *ME3* predicted enhancer. The risk variant is uniquely
774 highlighted with purple and all other SNPs are highlighted by their r^2 . The overlapped open
775 chromatin peaks of 13 retinal cell types were shown in the middle. Anchor regions of the retina
776 were highlighted with an orange or blue rectangle and red arcs show the enhance-gene pairs
777 predicted by Activity-by-Contact model. Genes in red and blue represent the sense and antisense

778 directions, respectively. The dashed line indicated the interested SNP position.

779 **Figure 4. Functional enrichment of pleiotropic causal genes and drug repositioning for the**
780 **treatment of ocular comorbidity.**

781 **A.** Gene ontology pathway enrichment analysis of pleiotropic causal genes. The size and color of
782 the circles indicated the number of causal genes and the significance in the corresponding pathway.
783 **B.** Protein-protein interaction (PPI) network of causal genes. The red text with larger nodes
784 indicated the pleiotropic gene in three diseases while the purple text indicated pleiotropic genes in
785 two diseases. The thickness of the edges represents the strength of evidence. **C. & D.** PPI
786 networks using disease-risk genes (red) and drug-targeted genes (purple and light gray). The nodes
787 in light blue ellipses represent the lateral drug target genes.










Tables

Table 1. The ten pleiotropic loci identified by cross-disease meta-analysis approaches


Chr	SNP ID	Position	<i>P</i> -value (ASSET)	A1	A2	Diseases	Nearest gene(s)
1	rs3766916	155049402	3.03E-09	T	C	glaucoma, AMD, cataract	<i>EFNA3</i>
3	rs35050931	150058352	6.69E-11	T	A	glaucoma, cataract	<i>TSC22D2</i>
5	rs17421627	87847586	1.83E-08	T	G	glaucoma, AMD	<i>LINC00461</i>
6	rs13191376	45522139	1.66E-09	C	T	glaucoma, cataract	<i>RUNX2</i>
7	rs12670840	116125172	7.52E-21	C	T	glaucoma, AMD, cataract	<i>CAV2</i>
9	rs944801	22051670	8.00E-42	G	C	glaucoma, cataract	<i>CDKN2B-AS1</i>
11	rs1619882	86363742	2.73E-17	C	A	glaucoma, AMD, cataract	<i>ME3</i>
11	rs11018564	89035134	2.89E-08	T	C	glaucoma, cataract	<i>TYR, NOX4</i>
15	rs1129038	28356859	5.26E-13	C	T	glaucoma, AMD, cataract	<i>HERC2</i>
19	rs146447071	818751	5.40E-09	T	C	glaucoma, cataract	<i>LPPR3</i>

A


medRxiv preprint doi: <https://doi.org/10.1101/2022.07.15.22277659>; this version posted August 26, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).

**B****C****D****E****F**


A




B




C




D




A




B




A



B



C



D

